Levi Strauss (LEVI) is bringing its blue jeans back to public markets. This week the company filed for an IPO that we estimate could raise $750 million, coming as early as March. It's no wonder Levi is going public, based on its 2017 and 2018...read more
Anchiano Therapeutics, a late-stage biotech developing therapies for early-stage bladder cancer, raised $31 million by offering 2.7 million ADSs at $11.50, below the expected price of $14.55. At $11.50, Anchiano Therapeutics would command a market cap of...read more
Railroad IPOs were hot in the 1850's, but two billionaires are bringing the industry back this week with an offering of Virgin Trains USA. In total, the week could see up to seven deals, but Virgin Trains USA's $510 million IPO is larger than the other six...read more
Anchiano Therapeutics, a Phase 3 biotech developing therapies for early-stage bladder cancer, announced terms for its IPO on Thursday. The Jerusalem, Israel-based company plans to raise $35 million by offering 2.4 million ADSs at a price of $14.55, the...read more
US IPO Weekly Recap: Blue jeans are back as Levi's preps March IPO
Levi Strauss (LEVI) is bringing its blue jeans back to public markets. This week the company filed for an IPO that we estimate could raise $750 million, coming as early as March. It's no wonder Levi is going public, based on its 2017 and 2018...read more
Micro-cap biotech Anchiano Therapeutics prices IPO at $11.50, below the expected price
Anchiano Therapeutics, a late-stage biotech developing therapies for early-stage bladder cancer, raised $31 million by offering 2.7 million ADSs at $11.50, below the expected price of $14.55. At $11.50, Anchiano Therapeutics would command a market cap of...read more
US IPO Week Ahead: On track for 7 IPOs, led by Virgin Trains USA
Railroad IPOs were hot in the 1850's, but two billionaires are bringing the industry back this week with an offering of Virgin Trains USA. In total, the week could see up to seven deals, but Virgin Trains USA's $510 million IPO is larger than the other six...read more
Micro-cap biotech Anchiano Therapeutics sets terms for $35 million US IPO
Anchiano Therapeutics, a Phase 3 biotech developing therapies for early-stage bladder cancer, announced terms for its IPO on Thursday. The Jerusalem, Israel-based company plans to raise $35 million by offering 2.4 million ADSs at a price of $14.55, the...read more